United Therapeutics Corporation Cash Flow Reinvestment Rate
United Therapeutics Corporation cash flow reinvestment rate. United Therapeutics Corporation (UTHR) has a Cash Flow Reinvestment Rate of 0.97x as of June 2026, reinvesting $304.20 Million (capex $108.00 Million plus investments $196.20 Million) from operating cash flow of $313.60 Million. Explore UTHR operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of United Therapeutics Corporation (2004–2025)
Cash flow reinvestment rate of United Therapeutics Corporation from 2004 to 2025. Historical reinvestment intensity for United Therapeutics Corporation across 20 annual periods. Explore United Therapeutics Corporation capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
United Therapeutics Corporation Cash Flow Reinvestment Rate by Year (2004–2025)
United Therapeutics Corporation cash flow reinvestment rate by year from 2004 to 2025. Year-by-year capital reinvestment analysis for United Therapeutics Corporation. For the full cash flow conversion analysis, see United Therapeutics Corporation cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | $560.60 Million | $1.56 Billion | $520.50 Million | ▼ -28.2% |
| 2024 | 0.50x | $663.70 Million | $1.33 Billion | $246.50 Million | ▼ -58.6% |
| 2023 | 1.21x | $1.18 Billion | $978.00 Million | $230.40 Million | ▲ +17.9% |
| 2022 | 1.02x | $822.40 Million | $802.50 Million | $138.80 Million | ▲ +25.9% |
| 2021 | 0.81x | $486.90 Million | $598.20 Million | $120.80 Million | ▼ -17.0% |
| 2020 | 0.98x | $740.90 Million | $755.70 Million | $59.30 Million | ▲ +17.3% |
| 2018 | 0.84x | $650.50 Million | $778.40 Million | $184.40 Million | ▼ -53.0% |
| 2017 | 1.78x | $844.00 Million | $474.20 Million | $86.30 Million | ▲ +750.4% |
| 2016 | 0.21x | $134.70 Million | $643.60 Million | $43.20 Million | ▼ -68.4% |
| 2015 | 0.66x | $253.16 Million | $382.80 Million | $49.79 Million | ▼ -45.8% |
| 2014 | 1.22x | $433.34 Million | $355.30 Million | $47.44 Million | ▲ +75.8% |
| 2013 | 0.69x | $294.97 Million | $425.27 Million | $31.91 Million | ▲ +37.4% |
| 2012 | 0.50x | $163.36 Million | $323.63 Million | $111.91 Million | ▲ +7.2% |
| 2011 | 0.47x | $117.78 Million | $250.19 Million | $35.98 Million | ▼ -55.4% |
| 2010 | 1.05x | $223.14 Million | $211.53 Million | $18.64 Million | ▲ +10.3% |
| 2009 | 0.96x | $95.40 Million | $99.72 Million | $95.40 Million | ▲ +21.1% |
| 2007 | 0.79x | $38.66 Million | $48.95 Million | $38.66 Million | ▲ +149.5% |
| 2006 | 0.32x | $15.63 Million | $49.39 Million | $15.63 Million | ▲ +123.4% |
| 2005 | 0.14x | $6.12 Million | $43.17 Million | $6.12 Million | ▼ -43.6% |
| 2004 | 0.25x | $5.22 Million | $20.78 Million | $5.22 Million | — |